Generated August 29, 2026.
Overview
IBB and XBI both track US-listed biotechnology companies via index ETFs, but they differ fundamentally in how they weight their holdings and manage risk. The equal-weight approach in XBI tilts the fund toward smaller positions within biotech and amplifies turnover, while IBB's market-cap structure concentrates holdings in the largest players.
How they differ
The biggest distinction is weighting methodology. XBI's equal-weight approach gives every holding roughly the same portfolio size regardless of market cap, which mechanically overweights smaller biotech names and requires rebalancing to stay equal-weighted. IBB's market-cap weighting lets largest positions grow organically with stock price. This cascades into volatility: XBI carries a beta of 1.14, meaning it typically swings 14% harder than the broader market, while IBB's 0.7 beta suggests it moves about 30% less dramatically.
Cost ranks a secondary difference. Both funds are small dividend payers—IBB yields 0.05% and XBI yields 0.07%—so income is not a draw here; both are total-return vehicles. AUM is comparable (XBI at $11.5B, IBB at $10.6B), though XBI has grown slightly larger since its later inception in 2006.
Who each is best for
IBB: Fits investors seeking lower volatility exposure to biotech's largest and most established names, with less need to rebalance around index methodology swings.
XBI: Designed for growth-oriented investors who tolerate higher volatility and want structural tilt toward smaller biotech positions, accepting the rebalancing mechanics that come with equal weighting.
Key risks to know
- Sector concentration: Both funds hold only biotechnology equities, concentrating risk into drug development cycles, FDA approval outcomes, and patent expirations across a single industry. Broader healthcare downturns or biotech funding droughts hit both hard.
- Volatility mismatch in XBI: Equal weighting forces XBI to systematically sell winners and buy losers to maintain position sizes, which can lock in losses during sustained market weakness and amplify drawdowns relative to market-cap peers.
- Small-cap tilt in XBI: The equal-weight methodology overweights smaller biotech companies that may carry higher liquidity risk, less analyst coverage, and greater vulnerability to clinical trial failures or capital constraints.
- Beta divergence: XBI's 1.14 beta means it will amplify losses during biotech sell-offs more than IBB's 0.7 beta will, making drawdown severity a material concern for risk-averse holders.
Bottom line
If you prioritize smoother returns and lower volatility, IBB's market-cap weighting and 0.7 beta stand out; if you want structural exposure to smaller biotech names and can tolerate higher swings, XBI's equal-weight methodology and lower expense ratio offer appeal. Neither is a meaningful income vehicle. Past performance doesn't predict future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
